Research on the Application Value of 18F-FDG PET/CT Combined with Neuronal Antibody Detection in the Diagnosis and Treatment of PNS Patients
-
摘要:
目的:探讨全身<sup<18</sup<F-FDG PET/CT联合神经元抗体检测在神经系统副肿瘤综合征(PNS)患者诊疗中的应用价值。方法:回顾性收集56例临床疑诊PNS患者的临床、神经副肿瘤抗体检测及全身<sup<18</sup<F-FDG PET/CT资料,对照病理及临床随访结果,利用ROC曲线评价PET/CT、神经元抗体及二者联合检测结果的诊断效能。结果:56例疑诊PNS患者中,共有肿瘤患者20例,其中肿瘤伴PNS 19例,肿瘤伴脊髓转移1例。<sup<18</sup<F-FDG PET/CT显像提示肿瘤或可能肿瘤23例,其中20例为真阳性,3例为假阳性(随访结果分别为反流性食管炎、反应性骨改变、颈部炎性病变),其余33例为真阴性;敏感度、特异度、准确度分别为100.0%、91.7%、94.6%。神经元抗体阳性33例,其中PNS伴肿瘤8例(抗Amphiphysin抗体脑炎3例,抗GABAB抗体脑炎2例,抗Yo抗体脑炎1例,抗Hu抗体脑炎2例),PNS不伴肿瘤25例(LGI1抗体脑炎10例,抗Amphiphysin抗体脑炎3例,抗Hu抗体脑炎1例,抗GABAB抗体脑炎3例,抗Yo抗体脑炎3例,抗CASPR2、GAD65、NMDA、PNMA及SOX1抗体脑炎各1例);神经元抗体阴性23例(其中伴肿瘤12例);敏感度、特异度、准确度分别为40.0%、30.6%、33.9%。两种联合检测结果的敏感度、特异度、准确度分别为100.0%、33.3%、57.1%,50.0%、94.4%、78.6%。ROC分析显示AUC分别为0.958(<i<P</i<<0.001;95%CI,0.904~1.000)、0.353(<i<P</i<>0.05;95%CI,0.199~0.506)、0.667(<i<P</i<<0.05;95%CI,0.528~0.806)及0.672(<i<P</i<<0.05;95%CI,0.514~0.830),<sup<18</sup<F-FDG PET/CT及两种联合检测方法具有统计学意义。结论:全身<sup<18</sup<F-FDG PET/CT可作为疑诊PNS患者无创筛查肿瘤的一线检查方法。
Abstract:Objective: To explore the clinical value of whole-body <sup<18</sup<F-FDG PET/CT combined with neuroantibody detection in the diagnosis and treatment of paraneoplastic neurological syndromes (PNS). Methods: Clinical, laboratory, and imaging data of 56 hospitalized patients with suspected PNS who underwent systemic <sup<18</sup<F-FDG PET/CT and neuropathic tumor antibody detection were retrospectively collected and followed-up on. ROC curve analysis was performed to compare the diagnostic efficacy of PET/CT, neuronal antibodies, and their combined detection results. Results: Among the 56 patients with suspected PNS, there were 20 with malignant tumors, including 19 cases complicated with PNS and 1 patient with spinal cord metastasis which also le d to neurological symptoms. <sup<18</sup<F-FDG PET/CT imaging indicated tumors or possible tumors in 23 cases, of which 20 cases were true positive, 3 cases were false positive (the follow-up results were reflux esophagitis, reactive bone changes, or inflammatory lesions in the neck), and the remaining 33 cases were true negative. The sensitivity, specificity, and accuracy of PET/CT were 100%, 91.7%, and 94.6%, respectively. There were 33 cases with positive neuroantibodies, including 8 cases of tumors with PNS (3 cases with anti-amphiphysin antibody encephalitis, 2 cases with anti-GABAb antibody encephalitis, 1 case with anti-Yo antibody encephalitis, and 2 cases with anti-Hu antibody encephalitis). Moreover, there were 25 cases without tumors (10 cases with LGI1 antibody encephalitis, 3 cases with anti-amphiphysin antibody encephalitis, 1 case with anti-Hu antibody encephalitis, 3 cases with anti-GABAb antibody encephalitis, 3 cases with anti-Yo antibody encephalitis, 1 case with Anti-caspr2, 1 case with GAD65, 1 case with NMDA, 1 case with PNMA, and 1 case with SOX1 antibody (1 case each). Of these, 23 cases were negative (12 cases with tumor). The sensitivity, specificity, and accuracy of the neuronal antibody test were 40.0%, 30.6%, and 33.9%, respectively. Furthermore, the sensitivity, specificity, and accuracy of the combined detection were 100.0%, 33.3%, 57.1%, 50%, 94.4%, and 78.6%, respectively. ROC analysis showed that the AUC was 0.958 (<i<P</i<=0.000<0.05; 95% CI 0.904~1.000), 0.353 (<i<P</i<=0.070>0.05; 95% CI 0.199~0.506), 0.667 (<i<P</i<=0.040<0.05; 95% CI 0.528~0.806), and 0.672 (<i<P</i<=0.034<0.05; 95% CI 0.514~0.830). Conclusion: Whole-body 18F-FDG PET/CT has the potential to be the first choice for noninvasive tumor screening in patients with suspected PNS.
-
Keywords:
- FDG /
- PET/CT /
- paraneoplastic syndrome /
- paraneoplastic antibody
-
肾上腺出血(adrenal hemorrhage,AH)是一种由多种原因引起的较少见的出血性疾病,因临床表现和实验室指标的不典型或多样性而常被误诊或漏诊。其中双侧肾上腺弥漫性出血(bilateral adrenal diffuse hemorrhage,BADH)更为罕见[1],其腹胁肋部和胸背部疼痛、发热、贫血、恶心呕吐和腹泻等临床表现不典型[2],导致误诊率高,且因发病急、进展快、病变多系统累及而预后不良,所以早期发现、精准诊断和鉴别极为重要。
新生儿肾上腺出血的研究比率相对成人高[3-5],临床对成人继发的BADH认知相对缺乏,本文收集我院诊治的2例由Systemic Lupus Erythematosus继发的BADH,并总结近10年国内外相关文献进行回顾性分析,旨在提高临床和影像医师对该病的认知和诊治水平。
1. 病例资料
1.1 病例1
1.1.1 临床表现与实验室检查
患者,女性,26岁,患者半月前受凉后出现上腹持续性胀痛,伴腰部疼痛、恶心,于当地医院就诊并对症治疗后症状无好转,建议转院治疗,患者出院后症状较前加重,出现单侧眼睑水肿,且再次出现发热,体温39.7℃,伴畏寒,无寒战。遂后主因上腹胀痛半月余,加重伴肛门停止排气排便、恶心呕吐4 d入我院进一步诊治。入院后上腹部疼痛及压痛明显,查体发现体温逐渐升高至38.7℃,背部可见网状青斑。
实验室检查:肌酐逐渐升高至633 μmol/L、尿素19.67↑(2.6~7.5 mmol/L)、估算肾小球滤过率7↓(90~120 ml/min/1.73 m2)、尿蛋白阳性,提示肾功能衰竭。肌红蛋白70.60↑(14.3~65.8 ng/mL)、肌钙蛋白I 160.8↑(≤11.6 pg/mL),提示心功能衰竭合并心肌损伤。血浆D二聚体
4951 ↑(<243 μg/L)、血浆凝血酶原时间16.2↑(8.8~11.8 s)、血浆凝血酶原活动度56.0↓(80%~130%)、活化部分凝血酶时间48.3↑(24~37 s),提示凝血功能异常。动脉血气分析PH 7.46↑(7.35~7.45)、二氧化碳分压27↓(35~45 mmHg)、碳酸氢根离子19.2↓(21.4~27.3 mmHg)、钠135↓(135~145 mmol/L)、总钙1.99↓(2.2~2.7 mmol/L),提示酸碱平衡代谢紊乱;总蛋白56.7↓(65~85 g/L)、白球比0.99↓(1.2~2.4),提示低白蛋白血症;红细胞2.68↓(3.8~5.1×1012/L)、血小板72↓(125~350×109/L)、血红蛋白浓度逐渐降低至61 g/L提示血细胞减少。白细胞16.12↑(3.5~9.5×109/L)、中性粒细胞百分比88.8↑(40%~75%)、C-反应蛋白持续处于较高水平,提示机体处于感染状态;免疫检查抗核抗体阴性。1.1.2 影像学检查
外院腹部CT平扫(2022-04-02):双侧肾上腺肢体增粗,以左侧为著,密度不均匀,可见结节样高密度影,CT值约50 HU,周围脂肪间隙模糊,肝缘可见积液(图1(a))。我院腹部CT平扫(2022-04-08):双侧肾上腺肢体明显增粗、肿大,左侧肢体厚度最宽处达1.3 cm,右侧肢体厚度最宽处达1 cm,密度略不均匀,CT值范围约28~34 HU,腹膜后脂肪间隙模糊,肠系膜水肿,多发浆膜腔积液,考虑感染或出血病变(图1(b)和图1(d))。
双侧肾上腺彩色多普勒超声检查:右侧肾上腺增厚,回声不均,周边软组织回声增强;左侧肾上腺区可见片状低回声,边界不清,周边软组织肿胀,CDFI示未见明显血流信号(图2(a)和图2(b))。单脏器灰阶立体成像:左肾上腺来源的混合回声病变,考虑肾上腺出血(图2(c))。双肾静脉彩色多普勒超声示双肾静脉未见异常(图2(d))。常规经胸心脏彩色多普勒检查:心包腔内极少量积液。
1.1.3 治疗
患者系统性红斑狼疮疾病活动度评分大于10分,综合其病史及相关检查,考虑系统性红斑狼疮累及肾脏、浆膜等多系统所致急性肾功能衰竭,以及影像学提示肾上腺出血,为狼疮危象,病情重可出现抗核抗体阴性。
对患者予以甲强龙500 mg静脉冲击联合赛可平0.5 g Bid,硫酸羟氯喹片0.2 g Bid治疗,辅以免疫球蛋白(20 mg QD)增强免疫力、罗氏芬(1 g qd)抗感染、制霉菌素预防口腔真菌感染、雾化吸入、护胃、积极补液、镇痛、输血等对症支持治疗,期间患者反复血肌酐升高、无尿,行血液透析、利尿等治疗,症状明显缓解,复查腹部CT平扫未见明显异常(图1(c)和图1(e)),尿量明显恢复,病情平稳,好转出院。
1.2 病例2
1.2.1 临床表现与实验室检查
患者,女性,58岁,因“间断憋气1年半,加重1月”入院。既往系统性红斑狼疮诊断明确。入院后第2 d夜间患者出现腹部胀痛并进行性加重,伴恶心、干呕。查体发现右腹压痛明显,肾区叩痛阳性。
实验室检查:尿素氮29.7↑(3.2~7.1 mmol/L)、肌酐237↑(41~73μmol/L)、尿酸533↑(89~257μmol/L)、尿蛋白+++,提示肾功能不全;白蛋白20.5↓(40~55 g/L),提示低白蛋白血症;血红蛋白逐渐降低至57 g/L,提示重度贫血;红细胞2.04↓(3.8~5.1×109/L)、血小板158↓(125~135×109/L),提示血细胞减少;白细胞17.1↑(3.5~9.5×109/L)、C-反应蛋白12.86↑(≤6 mg/L)、血沉 > 140↑(0~20 mm/hr),提示机体处于感染状态;钾5.68↑(3.5~5.3 mmol/L)、钠134↓(135~145 mmol/L)、氯112↑(99~110 mmol/L),提示电解质紊乱;血浆D-二聚体
2515 ↑(<243μg/L)、血浆凝血酶原活动度132↑(80%~130%),提示凝血功能异常;免疫检查抗核抗体阳性,抗双链DNA抗体阳性。1.2.2 影像学检查
腹部CT平扫:腹膜后沿腔静脉向下走行达右侧髂血管旁可见团片影,部分节段密度增高,CT值达53 HU,病变并累及右肾周,向左达腹主动脉左侧,大部分包绕下腔静脉、右肾静脉(图3(a)和图3(d))。
血管超声造影:腹膜后下腔静脉后方低回声,无血流,考虑肾上腺来源可能性大;左肾静脉血栓延伸至下腔静脉,下腔静脉狭窄伴侧支开放。
双肾血管超声:动静脉血流通畅,双肾动脉血流速度减低。
1.2.3 治疗
患者系统性红斑狼疮、狼疮性肾炎、肾上腺出血、低蛋白血症、肾功能不全、重度贫血诊断明确,在积极应用激素、环磷酰胺等抗炎、抗免疫治疗原发病的基础上,及时补充浓缩红细胞,并动态观察2 d无活动性出血,加用拜瑞妥10 mg/d继续抗凝治疗。临床症状逐渐缓解。
出院前复查腹部CT平扫提示肾上腺来源血肿范围较前缩小(图3(b)和图3(e)),出院1个月后复查腹部CT提示未见明显异常(图3(c))。
2. 讨论
肾上腺是位于肾脏上方和脊柱两侧腹膜后间隙内成对的内分泌腺,其血供丰富,每分钟流经的血量相当于自重的7倍[6]。其供血动脉分为上、中、下3支,分别起源于膈下动脉、腹主动脉和肾动脉,主干发出许多分支形成被膜下动脉丛深入皮髓质内。回流静脉则是一条中央静脉经肾上腺门部分别回流至下腔静脉和左肾静脉,由此形成了丰富的动脉供血(3支)与相对有限的静脉引流(1支)独特的“血管坝”(vascular dam)结构[7]。这种血管的特殊性可能与神经递质和内分泌激素的循环、皮质和髓质的功能调控以及肾上腺出血的机制等密切相关。
肾上腺出血的病因和发病机制尚不明确,临床上依据病因分为外伤性出血(traumatic adrenal hemorrhage)和非外伤性出血(nontraumatic adrenal hemorrhage)两种类型,其中外伤性出血,因肾上腺体积小、位置深以及周围被丰富的脂肪结缔组织包裹,外伤导致其直接损伤出血极为罕见。所以,多学者认为可能与肾上腺静脉血管内压力突发升高的直接传导作用,以及应激状态下分泌大量肾上腺皮质激素及儿茶酚胺引起的引流小静脉强烈收缩、静脉压力升高和血液易凝状态导致的肾上腺血栓形成有关[8-9]。此类型出血多为单侧或双侧的局限性出血性病变,右侧肾上腺中央静脉直接汇入下腔静脉而常受累及。
非外伤性出血,指无外伤因素的肾上腺组织损伤、渗出、肿胀和出血等一系列改变,常见于高血压危象、感染和妊娠的应激状态、结缔组织疾病、血液系统疾病、系统性或肾上腺肿瘤性疾病、相关免疫性药物或抗凝剂导致凝血功能异常和不明原因的自发性肾上腺出血等[10-11]。其发病机制和病理改变除了上述应激状态下激素作用有关,还可能与血管免疫功能异常、小血管炎或微血栓形成、毛细血管基底膜破坏和通透性增加,以及继发性凝血功能障碍等有密切关系。此类型出血可表现为单纯或双侧局限性、多发性或弥漫性出血等多样化,尤以双侧肾上腺弥漫性出血为重,常伴有周围脂肪层或腹膜后腔隙浸润和多浆膜腔病变,预后较差。本文2例患者均属于重症SLE合并肾上腺继发性出血。
(1)临床特点。BADH早期临床表现非特异的腹胁肋部和胸背部疼痛、发热、贫血、恶心呕吐和腹泻等,进而快速发展为肾上腺皮质功能不全或急性肾上腺危象,呈现持续性高热、严重低血压、低血容量性休克、脏器衰竭,临床上常误诊为消化道相关的急腹症或其他疾病而错过最佳治疗[12-13]。
(2)影像学方法及表现特征。肾上腺出血因其临床表现不典型及多样,病理不易获得,诊断相对困难,因此需依靠影像学检查协助并明确诊断,其中尤以腹部CT平扫为先,其操作简单、无需注射对比剂和较好的诊断敏感性及特异性,成为诊断肾上腺出血类型、程度和性质,以及评估重症患者肾上腺危象的首选方式[14]。
肾上腺出血的CT表现与临床分期、病变程度密切相关,临床上根据病程一般分为3期:急性期(7 d内)、亚急性期(1~7 w)及慢性期(大于7 w);根据病变程度和范围分为局限性和弥漫性等两种。①局限性肾上腺出血,急性及亚急性期表现为单侧或双侧卵圆形或圆形或梭形,稍高密度(CT值50~90 HU)或混合或等密度肿胀、结节或肿块影,增强扫描无强化,边缘清晰或不规则,肾上腺周围脂肪组织多正常或轻度浑浊;慢性期密度减低或囊性病变或伴有钙化,部分肾上腺体积可恢复正常或缩小[15-16]。②BADH,急性及亚急性期表现为双侧肾上腺肢体肿胀,呈结节状、不规则形、弥漫性混合或稍高密度(CT值50~90 HU),增强扫描无强化,边缘不规则或模糊不清,肾上腺或肾脏周围脂肪组织及腹膜后呈现不同程度絮状或网格状或片状浑浊或模糊影、大量渗出或积液影,系大量出血浸润周围脂肪或疏松结缔组织所致。病变进展则肾上腺增大、密度减低或混杂密度,周围累及范围广泛和出血渗出加重,常伴有腹水、胸水和心包积液以及肺内异常等多系统病变;病变好转肾上腺体积缩小、密度减低和边缘渐清,极少囊变或钙化,周围渗出或水肿逐渐减少和吸收。
(3)鉴别诊断。BADH的病变形态、密度和体积的动态性演变均有利于其确诊和与其他病变进行鉴别。主要鉴别的病变是肾上腺本身的增生及肿瘤,包括肾上腺皮质增生、皮质腺瘤、嗜铬细胞瘤和转移瘤。
肾上腺皮质增生主要表现为双侧肾上腺弥漫性增大,其外形、密度及信号保持正常;肾上腺皮质腺瘤主要表现为单侧肾上腺类圆形或椭圆形肿块,体积较小,其内富含脂类物质平扫密度较低,且可出现残肢及对侧肾上腺萎缩性改变;肾上腺嗜铬细胞瘤主要表现为单发圆形或类圆形肿块,体积多较大,出血坏死囊变多见,其密度不均匀且增强扫描呈不均匀明显强化;肾上腺转移瘤则有原发肿瘤病史,表现为双侧肾上腺多发结节或肿块,密度类似原发肿瘤,且会合并其他部位转移。而腹膜后脂肪组织弥漫性病变如淋巴水肿及纤维化当其包绕或累及双侧肾上腺时与BADH鉴别较为困难,需要结合临床症征、实验室检查和多模态影像等综合分析。
3. 总结
肾上腺出血较为罕见,BADH是需要早期发现和精准诊断的急腹症或重症疾病。当临床表现为非特异性持续性腹胸部剧痛、持续高热、不明原因的贫血、恶心呕吐、严重低血压或低血容量性休克等表现时,且对症治疗效果不佳,急查腹部CT平扫发现双侧肾上腺弥漫肿胀或肾上腺边缘模糊且腹膜后大量渗出时,应考虑到合并BADH的可能,情况允许,则加扫腹部CT增强检查。以周为时间单元的CT平扫显示病变的形态、密度、体积和周围等特有的动态性演变,是确诊BADH和鉴别的重要指标。
-
表 1 疑诊PNS患者神经元抗体检测结果分析
Table 1 Analysis of the detection results of the neuronal anstibodies in suspected PNS patients
神经元抗体
检测结果合并肿瘤情况 病例数/例 神经元抗体类型/病例数(例) 阳性 肿瘤患者 8 抗Amphiphysin抗体脑炎3例,抗GABAB抗体脑炎2例,抗Yo抗体脑炎1例,抗Hu抗体脑炎2例 非肿瘤患者 25 LGI1抗体脑炎10例,抗Amphiphysin抗体脑炎3例,抗Hu抗体脑炎1例,抗GABAB抗体脑炎3例,抗Yo抗体脑炎3例,抗CASPR2、GAD65、NMDA、PNMA及SOX1抗体脑炎各1例 阴性 肿瘤患者 12 — 非肿瘤患者 11 — 表 2 18F-FDG PET/CT检查、神经元抗体检测及联合检测1、2与病理及随访结果对照
Table 2 Comparison of 18F-FDG PET/CT, neuronal antibody detection, and combined detection 1 and 2 with the pathological and follow-up results
检查方法 病理及随访 敏感度/% 特异度/% 准确度/% (+) ( − ) 合计 18F-FDG PET/CT检查 100.0 91.7 94.6 (+) 20 3 23 ( − ) 0 33 33 合计 20 36 56 神经元抗体检测 40.0 30.6 33.9 (+) 8 25 33 ( − ) 12 11 23 合计 20 36 56 联合检测1 100.0 33.3 57.1 (+) 20 24 44 ( − ) 0 12 12 合计 20 36 56 联合检测2 50.0 94.4 78.6 (+) 8 2 10 ( − ) 12 34 46 合计 20 36 56 -
[1] YAN J, CHEN Z, LIANG Y, et al. Anti-CV2/CRMP5 antibody-positive paraneoplastic neurological syndromes with chronic intestinal pseudo-obstruction in a small-cell lung cancer patient: A case report and literature review[J]. The Journal of International Medical Research, 2020, 48(12): 1220774018.
[2] SUNDERMANN B, SCHRODER J B, WARNECKE T, et al. Imaging workup of suspected classical paraneoplastic neurological syndromes: A systematic review and retrospective analysis of 18F-FDG-PET-CT[J]. Academic Radiology, 2017, 24(10): 1195−1202. doi: 10.1016/j.acra.2017.03.022
[3] SHEIKHBAHAEI S, MARCUS C V, FRAGOMENI R S, et al. Whole-body 18F-FDG PET and 18F-FDG PET/CT in patients with suspected paraneoplastic syndrome: A systematic review and Meta-analysis of diagnostic accuracy[J]. Journal of Nuclear Medicine, 2017, 58(7): 1031−1036. doi: 10.2967/jnumed.116.183905
[4] BINKS S, Uy C, HONNORAT J, et al. Paraneoplastic neurological syndromes: A practical approach to diagnosis and management[J]. Practical Neurology, 2022, 22(1): 19−31. doi: 10.1136/practneurol-2021-003073
[5] LAMBERT N, LUTTERI L, SADZOT B, et al. Paraneoplastic neurological syndromes[J]. Revue Médicale de Liège, 2021, 76(5/6): 413−418.
[6] FU P, HE L, TANG N, et al. A single center retrospective study of paraneoplastic neurological syndromes with positive onconeural antibodies[J]. Journal of Clinical Neuroscience, 2021, 89: 336−342. doi: 10.1016/j.jocn.2021.05.027
[7] 冉艳萍. 儿童中枢神经系统副肿瘤综合征的研究进展[J]. 国际儿科学杂志, 2020,47(8): 552−555. doi: 10.3760/cma.j.issn.1673-4408.2020.08.009 RAN Y P. Research progress of paraneoplastic syndrome of central nervous system in children[J]. International Journal of Pediatrics, 2020, 47(8): 552−555. (in Chinese). doi: 10.3760/cma.j.issn.1673-4408.2020.08.009
[8] OPALINSKA M, SOWA-STASZCZAK A, WEZYK K, et al. Additional value of 18F-FDG PET/CT in detection of suspected malignancy in patients with paraneoplastic neurological syndromes having negative results of conventional radiological imaging[J]. Journal of Clinical Medicine, 2022, 11(6): 1537.
[9] DALMAU J, GEIS C, GRAUS F. Autoantibodies to synaptic receptors and neuronal cell surface proteins in autoimmune diseases of the central nervous system[J]. Physiological Reviews, 2017, 97(2): 839−887. doi: 10.1152/physrev.00010.2016
[10] MASSA F, FILIPPI L, BENEDETTI L, et al. FDG PET Unveils the course of paraneoplastic cerebellar degeneration: A semiquantitative analysis[J]. Clinical Nuclear Medicine, 2021, 46(6): e327-e328.
[11] 刘磊, 杨文秋, 王保平, 等. 貌似运动神经元病的神经系统副肿瘤综合征1例报告及文献分析[J]. 中风与神经疾病杂志, 2021, 38(3): 258-259. LIU L, YANG W Q, WANG B P, et al. A case report and literature analysis of paraneoplastic syndrome of nervous system resembling motor neuron disease[J]. Journal of Stroke & Neuropathy, 2021, 38(3): 258-259. (in Chinese).
[12] 孙江, 王兴臣, 姬琳, 等. 以周围神经病变为首发症状的神经系统副肿瘤综合征1例报道并文献复习[J]. 中华全科医学, 2021, 19(12): 2158-2159. SUN J, WANG X C, JI L, et al. A case report of paraneoplastic syndrome with peripheral neuropathy as the first symptom and literature review[J]. Chinese Journal of General Practice, 2021, 19(12): 2158-2159. (in Chinese).
[13] KRISTENSEN S B, HESS S, PETERSEN H, et al. Clinical value of FDG-PET/CT in suspected paraneoplastic syndromes: A retrospective analysis of 137 patients[J]. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42(13): 2056−2063. doi: 10.1007/s00259-015-3126-2
[14] 伊骏飞, 郝洪军, 刘琳琳, 等. 神经系统副肿瘤综合征与神经副肿瘤抗体分析[J]. 中国神经免疫学和神经病学杂志, 2020,27(2): 104−108. doi: 10.3969/j.issn.1006-2963.2020.02.005 YI J F, HAO H J, LIU L L, et al. Analysis of paraneoplastic syndrome in nervous system and its antibody[J]. Chinese Journal of Neuroimmunology and Neuropathy, 2020, 27(2): 104−108. (in Chinese). doi: 10.3969/j.issn.1006-2963.2020.02.005
[15] ISHIKAWA H, SHINDO A, NIWA A, et al. Long-term MRI changes in a patient with Kelch like protein 11-associated paraneoplastic neurological syndrome[J]. Journal of the Neurological Sciences, 2021, 28(12): 4261-4266.
[16] MASANGKAY N, BASU S, MOGHBEL M, et al. Brain 18F-FDG-PET characteristics in patients with paraneoplastic neurological syndrome and its correlation with clinical and MRI findings[J]. Nuclear Medicine Communications, 2014, 35(10): 1038-1046.
[17] 康磊, 徐小洁, 马超, 等. FDG PET/CT在诊断神经系统副肿瘤综合征的研究进展[J]. 中国肿瘤临床, 2014,41(10): 667−670. doi: 10.3969/j.issn.1000-8179.20140196 KANG L, XU X J, MA C, et al. Research progress of FDG PET/CT in diagnosis of paraneoplastic syndrome of nervous system[J]. Chinese Journal of Oncology, 2014, 41(10): 667−670. (in Chinese). doi: 10.3969/j.issn.1000-8179.20140196
[18] GRAUS F, DALMOU J, RENE R, et al. Anti-Hu antibodies in patients with small-cell lung cancer: Association with complete response to therapy and improved survival[J]. Journal of Clinical Oncology, 1997, 15(8): 2866−2872. doi: 10.1200/JCO.1997.15.8.2866